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weakness leading to loss of ambulation and progression to death by pulmonary and cardiac dysfunction. It has
been documented both steroids deflazacort and prednisone delay muscle degeneration but not many studies
outline the differences between the two including side effect profiles. Deflazacort is not yet available in the US.
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dystrophy, deflazacort and prednisone. Articles that consisted of the outcomes of muscle function, cardiac and
pulmonary changes, side effect incidence and type, and gene expression in whole blood were included. The
literature was assessed using the GRADE system to rate its quality and importance.
Results: Four articles were selected for review. There were no significant differences between the two steroids
in treating muscle functionality, prevention of cardiomyopathy or difference in pulmonary function. In
Bonifati et al and Balaban et al, weight gain in prednisone-treated patients was greater than with deflazacort.
With regards to gene expression, Lit et al discovered gene probes in the prednisone-treated patients which
promote weight gain. On the other hand, deflazacort probes are suspected to prevent obesity.
Conclusion: It is clear both steroids are efficacious in treating DMD but side effects will determine patient
and providers’ choice of prescription. Further research with randomized control trails over extended time
periods is needed to establish the true difference between side effects of deflazacort and prednisone. Research
in gene expression holds promise for future utility in the selection of steroid therapy.
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Abstract   
 
Background:  Duchenne muscular dystrophy (DMD) is a genetic disorder in males resulting in 
muscle weakness leading to loss of ambulation and progression to death by pulmonary and 
cardiac dysfunction. It has been documented both steroids deflazacort and prednisone delay 
muscle degeneration but not many studies outline the differences between the two including side 
effect profiles. Deflazacort is not yet available in the US. This systematic review compiles recent 
data to compare deflazacort to prednisone in the treatment of DMD boys. 
Method:  A full search of medical literature using multiple databases, MEDLINE, CINAHL, 
Evidence Based Reviews Multifile and Web of Science, and reference lists was conducted with 
the key words muscular dystrophy, deflazacort and prednisone.  Articles that consisted of the 
outcomes of muscle function, cardiac and pulmonary changes, side effect incidence and type, and 
gene expression in whole blood were included. The literature was assessed using the GRADE 
system to rate its quality and importance. 
Results:  Four articles were selected for review.1-4 There were no significant differences between 
the two steroids in treating muscle functionality, prevention of cardiomyopathy or difference in 
pulmonary function. In Bonifati et al1 and Balaban et al,2 weight gain in prednisone-treated 
patients was greater than with deflazacort. With regards to gene expression, Lit et al4 discovered 
gene probes in the prednisone-treated patients which promote weight gain. On the other hand, 
deflazacort probes are suspected to prevent obesity. 
Conclusion:  It is clear both steroids are efficacious in treating DMD but side effects will 
determine patient and providers’ choice of prescription. Further research with randomized control 
trails over extended time periods is needed to establish the true difference between side effects of 
deflazacort and prednisone. Research in gene expression holds promise for future utility in the 
selection of steroid therapy. 
Keywords:  Duchenne muscular dystrophy, steroids, deflazacort, prednisone 
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Deflazacort Versus Prednisone: A Systematic Comparison of two Steroids in the 
Treatment of Duchenne Muscular Dystrophy 
 
BACKGROUND 
Duchenne muscular dystrophy (DMD) is an x-linked genetic pediatric disorder only 
affecting males involving the deletion or mutation of the Xp21 gene which produces the 
dystrophin protein. This crucial protein supports cell wall structure. Over time, a lack of 
functioning dystrophin leads to muscle cell weakness and degeneration with evident signs in 
patients as young as 6 years of age. It is theorized humoral and cellular immune responses in 
DMD contribute to the pathologic process of muscle cell wasting; further cell breakdown is 
produced by macrophages, cytotoxic t-cells, complement activation, and HLA class 1 antigens 
causing additional t-cell mediated attack. This damage to muscle cells has drastic implications on 
patients with muscle decline and can lead to loss of ambulation by 13 years of age,5 progression 
of scoliosis once this has occured and cardiac and pulmonary function deterioration, resulting in 
reduced life expectancy.6  
In 20% of DMD children, death is caused by cardiac complications.6,7 Ninety percent of 
children with DMD have significant cardiac progression8 with 20-30% showing evidence by the 
age of 10.9,10 The test to first show detectable cardiac changes in DMD is the electrocardiogram 
(EKG) and these changes can be seen almost universally by 12 years of age.11 Q-waves in lateral 
and inferolateral leads,12-14 increased voltage in right precordial leads,15 abnormalities in 
repolarisation, and an increased cardiomyopathic index14 are four signs in the EKG showing 
cardiac damage. The Echocardiogram is the standard screening method for DMD cardiomyopathy 
which shows ventricular systolic dysfunction with a defect leading to chamber dilation.13 Other 
cardiac complications in DMD patients include sinus tachycardia,16 prolonged QT intervals,17 and 
risk of emboli due to immobilization.5 Cardiac biopsies in DMD children show hypertrophic 
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cardiomyocytes with increased internal nuclei, endocardial and interstitial fibrosis with 
cytoplasmic lipofuscinosis and focal lymphocytic infiltration, large pleomorphic bizarre nuclei, 
and vacuoles and focal necrosis.18  Post-mortem cardiac tissue fiber analysis shows fibers are 
replaced by connective tissue and extensive myocardial fibrosis.8,19  
Pulmonary dysfunction is the second deadly complication in DMD children. Pulmonary 
function decline begins with respiratory muscle weakness in the late teens. Nocturnal 
hypoventilation develops and eventually respiratory failure ensues. If patients continue untreated, 
death occurs in the late teens to twenties. However, treating with ventilation support can prolong 
life into the fourth decade.5  
This raises the question how steroids affect DMD and prolong life suspending cardiac 
and pulmonary damage. Because DMD is a muscle wasting disease, treatment by steroids focuses 
on slowing the progression of muscle cell wall damage. Steroids have an anti-inflammatory, 
immunosuppressive affect.20  Specifically, steroids inhibit muscle proteolysis,21,22 stabilize muscle 
fiber membranes23 and increase myogenic repair.24 They reduce cytosolic calcium 
concentrations,25-27 and differentiate regulation of genes in muscle fibers.28 These actions, with 
suppression of the humoral and cellular immune responses, help to slow the progression of 
disease. In addition, steroids leave expression probes in whole blood which allow for deeper 
analysis of the functioning of each steroid.29  
Today, the standard of care is to treat DMD patients with steroids. Deflazacort and 
prednisone, two steroids with similar chemical structures and relatively similar side effect 
profiles, are currently used in the treatment of DMD children. Deflazacort is not available in the 
US but is being used in Canada and Europe where most of the current literature on deflazacort is 
being produced. Deflazacort has demonstrated fewer adverse effects30 and parents will order it 
from outside the US for treatment of their children at provider suggestion. Other families 
ultimately decline the use of any steroid to avoid side effects. Established dosing schedules have 
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still not been determined for either steroid with many studies presenting regimens to decide the 
best routine which both optimizes treatment outcomes while minimizing unwanted side effects. 
Most literature has been unable to state whether deflazacort is safer than, as efficacious as or 
carries the same risk of harm as prednisone. This systematic review attempts to compile studies 
that do adequately compare the two and report an overall consensus of conclusions. The goal is to 
highlight all outcomes to help support medical providers with decisions in regards to DMD 
treatment.  
METHODS 
Initial Search 
A thorough and complete search of the literature was conducted for relevant research 
using the databases MEDLINE, CINAHL, Evidence Based Medicine Reviews Multifile and Web 
of Science. The key words used were muscular dystrophy, prednisone and deflazacort. An 
examination of titles and abstracts was conducted looking for relevant articles and collected as 
additional background sources. In the reference sections, all articles including the background 
sources and a similar systematic review were searched for further studies.  
Eligibility Criteria 
Studies must have been DMD pediatric male patients who were being treated with either 
prednisone or deflazacort and must have contained comparison statistics. Patient diagnostic 
criteria and evaluation for DMD had to be incorporated and assessed. Because of the progression 
of this disease and the limited amount of evidence reported, observational studies were included 
along with randomized control trials. Any and all study outcomes were considered to fully assess 
the comparison of the two steroids. The studies were excluded if they had other patient 
populations or did not specifically compare the two steroids one to the other.  
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Quality Assessment 
The quality of literature was assessed using the GRADE system. GRADE evaluates 
studies based on design, execution, description, and explanation of data in the study.  
RESULTS 
Summary 
The search strategy resulted in a total of 115 articles. After examination of titles and 
abstracts, four articles were selected for review.1-4 Of the four studies included, one is a 
randomized control trial and three are retrospective cohort studies. Two studies1,2 are of moderate 
quality and two studies3,4 are very low quality. Because of the importance and relevance of this 
data to the DMD population and the limited studies available, very low quality studies were 
included knowing the conclusions presented are not definitive. Table 1 highlights the quality of 
each article and its importance. One study of moderate quality, Bonifati et al,1 collected data 
outside the US in Italy. Table 2 focuses on the key characteristics of each study assessed. Table 3 
focuses on the key outcomes from each study. Studies are reviewed in chronological order 
according to publication date.  
Bonifati et al 
Bonifati et al1 is a randomized, double-blind study conducted over 12 months in Italy in 
2000 with a sample size of 25 children. Patients were stratified by age and disease severity with 
both the patients and medical providers blinded to the use of either deflazacort or prednisone. 
There are 18 children treated with steroids, but the study does not state how many patients are in 
each specific steroid group. Inclusion criteria prevented patients from previous steroid use to 
enter the study. All patients were of similar ages and functional parameters; at baseline and 
throughout the study, biochemical and neurological screenings were conducted. Outcomes 
assessed include muscle strength and functional score, and significant side effects.  There is one 
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loss to follow-up in the prednisone group due to loss of ambulation. The study corrects for 
differences in weight by suggesting a diet to the subjects.1  
The results show there are no significant differences between steroids in terms of muscle 
strength and function. Both steroids significantly improve or delay muscle weakness. The study 
notes deflazacort has higher muscle assessment scores overall but it is not deemed a significant 
difference to prednisone. It suggests this may be due to the deflazacort group having better 
baseline values.1 
There is, however, a significant difference in side effect profiles in this study. The 
prednisone group has a significant increase in weight gain compared to the deflazacort group. At 
six months, the first significant difference is seen as a percentage increase in weight from 
baseline. This trend continues on into the ninth month with 5% gain in the deflazacort group and 
18% in the prednisone group and to a year with 9% gain in the deflazacort group and 21.3% gain 
in the prednisone group. The study also notes four patients taking prednisone had an increase in 
weight of over 20% of baseline but only one deflazacort patient did.1 
In regards to other side effects, behavior changes, appetite increase, and the appearance 
of cushingoid features, all slightly increased but stayed equal between both groups. One child 
taking deflazacort reported a traumatic bone fracture whereas prednisone children had no 
fractures during the study. Cataracts were reported in both groups with two in deflazacort patients 
and one in a prednisone patient. All laboratory parameters remained either equal or unchanged in 
both groups.2 
Balaban et al 
The second study, Balaban et al,2 published in 2005, is a retrospective cohort study of 
DMD boys conducted over seven years. The age range of 12-15 years is the age when patients 
finished the study. Data was collected from Colorado. Patients were not randomized; the family 
determined treatment after discussing with a medical provider the side effects and cost of each 
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medication. The article purposely emphasizes families choosing prednisone over deflazacort due 
to cost alone. Prognostic factors were relatively equal due to the nature of the DMD patient 
population. Balaban et al2 assesses muscle strength and functionality, pulmonary efficiency, 
weight gain, cataracts, fractures, behavior changes and the presence of severe scoliosis with the 
recommendation for surgery.2 
The main focus of the study was muscle functionality over time. There are two 
differences between prednisone and deflazacort groups. One is the deflazacort group’s change in 
grip strength over the ages 10-15years which significantly increased (p<0.05). The second is the 
prednisone group had considerable improvement in pinch strength (p<0.05). All other values 
were relatively equal when comparing the steroids to each other. A note that is not statistically 
significant but important to mention is deflazacort patients had overall higher absolute muscle 
testing score values compared to prednisone. Additionally, this study compares each steroid to 
control values. Deflazacort boys were stronger compared to controls upon completion of the 
study, but prednisone boys were not. Overall, both groups preserved upper limb strength 
compared to controls.2 
Weight gain was another major factor in this study. Deflazacort patients reported early 
weight gain at the beginning of the trial into the 25th and 50th percentiles at age 10. Prednisone 
patients at age 10 had weight gain into the 75th and 90th percentiles. By 12 years of age, 
deflazacort patients were holding steady in the 50th to 75th percentiles. Prednisone children at 12 
years of age stayed in the 75th and 90th percentiles. Three prednisone treated boys had medication 
decreased or discontinued due to the unhealthy weight gain. No deflazacort patients had a change 
in medication dosage for weight.2 
This trial considered pulmonary function. While it is clear that both steroids significantly 
improved compared to controls, no significant divergence is found between the two steroid 
groups. Even though it is not significantly different, the article does say deflazacort children 
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continued to have increasing forced vital capacity in the 10-15 year old age range whereas the 
prednisone children remained unchanged.2 
Over the 7 year study period, scoliosis was continually assessed and managed as well. 
Deflazacort patients never met criteria for surgery. Two prednisone patients met conditions but 
only one had a scoliosis surgery while the family declined in the second case.2 
Both groups had dosage tapers or discontinuations due to other side effects. The 
prednisone groups had one patient with a fracture and three patients with behavior changes. The 
fracture case and one of the behavior changing patients had dose tapering or discontinuation, not 
specifically specified by the article. The deflazacort group had one fracture, one behavior change 
patient and one patient with hypertension. All three of these subjects had tapering adjustments 
made.2 
Markham et al 
Markham et al3 is a study collecting data in 2005, which strictly focuses on cardiac 
function in DMD patients and its relationship to steroids. Done in the US, it is a retrospective 
cohort which collected previous data on any DMD patient that had an echocardiogram assessing 
shortening fraction. Any patient under the age of 22 at the time of testing was included. This 
allowed for a statistically significant difference between the ages of the steroid groups with 
deflazacort patients being younger than the prednisone patients. The other prognostic factors 
including treatment length, weight, BMI, systolic and diastolic pressure and left ventricular end 
diastolic dimensions were equal.3  
The results of Markham et al3 show both groups to be equal. Whether a patient is on 
deflazacort or prednisone, the article’s results show both steroids prevent cardiomyopathic 
progression. Both prednisone and deflazacort, even if discontinued after four years of treatment, 
still have cardiac protection for up to an additional six years.3 
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Lit et al 
The last study published in 2008 takes a unique look at how steroids affect DMD 
patients. Lit et al4 concentrates on whole blood gene expression. After collecting whole blood 
from 34 DMD patients, it is analyzed to determine how each steroid is expressed and if the 
samples can be differentiated one from the other. To test identification via genetic probes, the 
analyst was blinded. Two special case patients had taken prednisone first then switched to 
deflazacort by the time of testing so their specimens were used to assess results.4 
Between steroid groups in expression, 508 probes were found to be statistically different. 
Deflazacort has probes with 478 lower expressions and 30 higher expressions than prednisone. 
Implementing these probes into a prediction analysis of microarrays system, 496 probes were 
found to completely separate deflazacort from prednisone. Further analysis of the two special 
case specimens with both steroids against the 508 probes revealed characteristics of prednisone 
expression. However, once tested with the 496 probes only one specimen was properly identified. 
Table 4 exhibits a ten-fold leave-one-out cross validation test displaying the accuracy of 
predicting the correct steroid based on the 496 probes.4 
The most relevant data identified by this study is the type of probes each steroid is 
expressing. Deflazacort expresses a retinoic acid receptor α associated with inhibition of 
adipocyte differentiation. Prednisone, in opposition, expresses probes related to lipid metabolism, 
adipose formation and energy homeostasis. There are multiple probes which inhibit lipolysis in 
adipose tissue represented in the prednisone group, as well as interleukin systems one and six 
which both are linked with obesity.4  
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DISCUSSION 
Muscle Function 
As expected, the two studies assessing muscle functionality both generally concluded the 
same results.1,2 Either steroid is sufficient in treating DMD children to prolong strength and 
ambulation. Despite the small differences in studies, both surprisingly state deflazacort has better 
absolute values compared to prednisone even though neither is statistically significant. With this 
statement it is perhaps necessary for further studies to evaluate and report if this could be 
significant either on a larger sample size or over a longer period of time. Because it is the gold 
standard to treat DMD patients with steroids it is perhaps more important to compare deflazacort 
and prednisone based on their side effects.  
Weight Gain 
Weight gain is the most substantially documented detrimental side effect from steroids to 
DMD boys in this review. Both Bonifati et al1 and Balaban et al2 show that prednisone 
significantly causes an increased gain in weight in the target population compared to deflazacort. 
Using Bonifati et al’s1 results for weight gain greater than 20% over baseline, the number needed 
to treat was three patients; meaning, treating three DMD children with deflazacort will get one 
better outcome in weight management than treating with prednisone. Because both groups have 
the same functional ability, it cannot be assumed the deflazacort group is more active compared 
to the prednisone group. This leads to the hypothesis that the drugs directly affect patient weight. 
Activity level, as a confounding variable, can be addressed in future studies by possibly assessing 
participants activity via questionnaire or even implementing a required activity class for a 
subgroup of each steroid.  
Lit et al4 gives the possible explanation for drastic differences in weight when defining 
gene expression probes for each steroid. Because prednisone expresses genetic probes in blood 
which are directly responsible for lipid metabolism and adipose formation,31 it can be suggested 
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that prednisone is directly causing the weight gain seen in the other studies. Conversely, 
deflazacort has gene probes for retinoic acid that reduces obesity.32,33 These two findings by Lit et 
al4 can explain why, in Balaban et al,2 deflazacort patients gained some initial weight but never 
became obese. Further research on whole blood genetic probes in this population may lead to 
more appropriate dosing regimens decreasing side effect incidence while maintaining therapeutic 
effect.  
Cardiac Health 
Cardiac function was only assessed in one study reviewed, Markham et al.3 It clearly 
defines both steroids as sufficient in prolonging cardiac cell health. By sustaining cell health, 
DMD children will have a longer life expectancy which is critical. This study does suggest further 
evidence is needed by assessing cardiomyopathy with other tests. Since background studies show 
EKGs detecting the first signs of cardiomyopathies in DMD children, it would be helpful to see if 
there are differences in EKGs in each steroid group which could further differentiate deflazacort 
and prednisone.  
Pulmonary Health 
Balaban et al2 is the only study to fully test lung function by measuring functional vital 
capacity regularly. In both drugs, functional capacity is preserved. Over time, it may be 
interesting to see if significant differences do develop since deflazacort did continue to increase 
vital capacity in the 10-15 year age range where prednisone continues to remain unchanged. 
Scoliosis 
Scoliosis was measured in Balaban et al2 but not the other studies. With regards to DMD 
populations this may be a colossal omission in the current literature. Scoliosis progression in the 
adolescent years of life only hinders pulmonary and cardiac functions which are the leading 
contributors to death. Once independent ambulation is lost all other major functions to preserve 
life begin to deteriorate in DMD boys. Both prednisone and deflazacort significantly delay 
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scoliosis progression according to Balaban et al.2 What was interesting but not deemed 
statistically significant during the seven year trial was that no deflazacort patients even met the 
criteria for scoliosis surgery where two prednisone patients did with one undergoing spine 
surgery. Further evaluation comparing deflazacort to prednisone with patients both ambulatory 
and non-ambulatory is warranted to define possible dissimilarities.  
Gene Probes 
In addition to the relevance of the specific gene probes identified linking weight gain in 
Lit et al,4 it is important to note 496 probes have been identified which can accurately 
differentiate deflazacort from prednisone. This new research should continue to help in the 
treatment of DMD patients.  
Minor Side Effects 
Many minor side effects were determined to be the same or not significant between the 
two steroid groups. Only Bonifati et al1 and Balaban et al2 reviewed side effect profiles.  
Cataracts - Both Bonifati et al1 and Balaban et al2 had patients with cataracts. Bonifati et al1 had 
two deflazacort patients and one prednisone patient with cataracts and Balaban et al2 had two and 
zero respectively. There was no statistical difference in either case. 
Fractures – Bonifati et al1 had one deflazacort patient with a fracture but no prednisone patients 
had fractures. Balaban et al2 in each group had one fracture which resulted in a decrease is 
medication dose for both.  
Behavior Changes – Balaban et al2 had a total of four patients with behavior changes. In all 
cases, dosage adjustments were necessary with one treated with deflazacort and three treated with 
prednisone. Bonifati et al1 reported changes in behavior in both groups but not to the point of 
changing prescriptions. It was disappointing neither study described the behavior changes. To 
decide if action is necessary, future studies should evaluate alterations in behavior and the 
correlation to each steroid in DMD males.  
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Cushingoid appearance – Bonifati et al1 noted similar changes in both groups. 
Appetite Increase – Bonifati et al1 recorded comparable appetite increases. This helps further 
support previous statements about compared weight gain. Since both groups have similar 
appetites, it cannot be assumed the prednisone patients were eating more than deflazacort patients 
to allow for the considerable distinction. One issue not addressed is matching participants in age 
and the relation to appetite. In most cases, young children do not have comparable appetites to 
teenagers.  
Hypertension – Hypertension was only assessed in the Balaban et al2 article. Because of 
hypertension, one deflazacort patient had to decrease medication dosage. There was no record of 
hypertension in any prednisone patients.  
Limitations of Study 
Each study had its own limitations which is one reason this review was necessary. Pulling 
them together does not essentially make the evidence stronger but does show where holes in 
literature need to be addressed.  
Bonifati et al1 is the only randomized control trial but it was conducted over only one 
year. It had a small sample size and failed to define the number of patients in each group. Because 
just one patient was removed from the prednisone group in mid-study, the data was significantly 
altered. That one patient from the beginning of the study was declining rapidly in performance 
and had to drop out from loss of independent ambulation. It is possible with a larger sample size 
this would not have had such drastic implications.  
Balaban et al2 is perhaps the best conducted study despite being an observational 
retrospective cohort study. The only risk of bias is from families choosing medication prescribed 
based on known side effects and cost. It is regrettable most families made their decision on cost 
alone. In future studies, it would be optimal if the study researchers could eliminate the cost 
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factor by providing free or equally priced drugs to patients which was of course not possible in 
this retrospective study.  
Markham et al,3 another observational retrospective study, was limited due to 
inconsistency in age of the two groups studied. If the mean age groups were not different it’s 
possible other conclusions could have been drawn. This damaged the study’s quality; even if it 
had significant differences between steroids, its evidence could not be taken as fact. 
The last study, Lit et al,4 is of moderate quality as an observational study. No major 
limitations were identified. The significance of the gene probes discovered is critical to 
understanding how these steroids are really affecting the DMD patients. As much ongoing 
research in this area as possible can only improve the knowledge base.  
CONCLUSION 
Implications for Practice 
The overall results of the combined studies are not able to reveal the absolute best steroid 
to treat DMD.  If providers are specifically interested in avoiding weight gain, deflazacort should 
be prescribed over prednisone. All other patient important outcomes are relatively equal. 
Although it is not definitive, it seems once approved for use in the US, overall, deflazacort may 
hold some advantages over prednisone in treating DMD children.  
Implications for Research 
This review stresses the importance of more research comparing deflazacort and 
prednisone in randomized trials. This is a time sensitive issue; once the importance of deflazacort 
is truly realized, additional trials need to be conducted to make it available to the US population. 
Because it is unethical to not treat DMD patients with steroids, trials cannot have controls, 
unfortunately hindering the quality of evidence. However, since it is fully supported both steroids 
work to prolong muscle functionality, protect against cardiomyopathy and sustain pulmonary 
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health, randomizing patients into deflazacort and prednisone would be appropriate. Additionally, 
DMD patients are already regularly examined by a cardiologist, pulmonologist and additionally 
orthopedists for muscle function and scoliosis. If patients are willing to be randomized into either 
steroid group and difference in cost is eliminated, the next step would be to harvest the data 
collected by their regular primary providers. A study of this nature would be most beneficial to 
both providers and patients.  
As technology and techniques improve more research in genetic testing in DMD patients 
will be valuable. There are many avenues to be explored and evaluated concerning genetic probes 
in whole blood and their implications in treating DMD children.  
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Bonifati et 
al1 RCT 
minus 1 
pt drop 
changed 
analysis 
0 0 
minus 1 
small 
sample 
0 0 
plus 1 
wt 
change 
0 moderate important 
Balaban et 
al2  
retrospective 
cohort 0 0 0 0 0 0 0 
plus 
1 moderate important 
Markham et 
al3 
retrospective 
cohort 0 
minus 1 
age 
difference 
0 0 0 0 0 0 very low critical 
Lit et al4 retrospective cohort 0 0 0 0 0 0 plus 1 0 moderate critical 
 
Table II. Key Characteristics 
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Bonifati et al1 RCT 18 7 5.2-14.6 1yr Italy 
1 loss of 
ambulation 
Balaban et al2  retrospective cohort 12 18 19 12.0-15 7yr CO   
Markham et al3 retrospective cohort 19 29 63 <22 single test 
OH, 
IO   
Lit et al4 retrospective cohort 6+-2 6+-2 20   single test 
CA, 
OH 
2 cross 
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Table III. Summary of Findings 
Table IV. Cross-Validation Result 
 
 
 
 
 
Table IV.  This cross-validation result shows that the 496 probes identified in Lit et al are both 
sensitive and specific in distinguishing between the two steroids, deflazacort and prednisone.  
  Bonifati et al1 Balaban et al2 Markham et al3 Lit et al4 
Outcomes Deflazacort Prednisone Deflazacort Prednisone Deflazacort Prednisone Deflazacort Prednisone 
Muscle Function same same 
change in grip 
strength 10-
15yrs  
pinch 
strength 
change 
  
  
Weight 
5% 
gain/9mo 
18% 
gain/9mo early gain  3 * 
9%/12mo 21.3%/12mo 
Wt Gain > 20% 1 4   
Cataracts 2 1 2 0 
Fractures 1 0 1* 1* 
Behavior Change same same 1* 3* 
Cushingoid  same same 
  Appetite 
Increase same same 
Hypertension 
  
1* 0 
Pulmonary same same 
Severe Scoliosis 0 2 
Cardiac 
Shortening 
Fraction 
  
36.6%+-
3.5 35%+-5.5 
Gene Expression 
  
 508 probes distinguish difference 
Specific Probes 
Identified 
increased 
retinoic 
receptor alpha,  
fewer 
expression 
changes 
increased probes 
for lipid 
metabolism and 
interleukin 1&6 
associated with 
obestiy 
* had to decrease or stop dose        
  Deflazacort Prednisone 
Number of Samples 6 6 
Correct Prediction 6 6 
Incorrect Prediction 0 0 
Sensitivity 100% 100% 
Specificity 100% 100% 
